Day 3 Program

General Session 2

Day 3: December 10, 2026

9:30 AM–11:45 AM CST

Hall 1

Session Details

Moderator

Richard C Zellars

Moderator

Alastair Thompson

GS2-1

Omission of Breast Surgery in HER2-Positive Primary Breast Cancer Achieving Clinical Complete Response After Anti-HER2-Based Therapy: Primary Results From the AMATERAS-BC Prospective Phase III Trial (JCOG1806)

Tomomi Fujisawa, Gunma Prefectural Cancer Center, Gunma, Japan

GS2-2

Discussant for 979

Henry M Kuerer, UT MD Anderson Cancer Center, Houston, TX

GS2-3

Prospect : post-operative radiotherapy omission in selected patients with early breast cancer trial (ANZ 1002). Final results.

Bruce Mann, The Royal Melbourne Hospital, Parkville, Australia

GS2-4

Neonod2 trial: initial oncologic outcomes following omission of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy

Corrado Tinterri, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

GS2-5

Results of the POSNOC Trial: Omission of Axillary Treatment in Patients Undergoing Breast-Conserving Surgery or Mastectomy with One or Two Sentinel Node Macrometastases

Amit Goyal, Royal Derby Hospital, Derby, United Kingdom